IVIG-PEG is under clinical development by Grifols Therapeutics and currently in Phase III for Primary Humoral Immune Deficiencies. According to GlobalData, Phase III drugs for Primary Humoral Immune Deficiencies have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how IVIG-PEG’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IVIG-PEG overview

IVIG-PEG is under development for the treatment of primary humoral immune deficiencies and WHIM syndrome. It is administered through intravenous route. The therapeutic candidate comprises of pegylated human immunoglobulin G.

For a complete picture of IVIG-PEG’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.